First, FAK is a downstream signaling component of KRAS, emphasizing its directly linked function in supporting the KRAS activity.[14, 42] Second, FAK inhibitors have been reported to exert preferential killing to KRAS mutant cancer.[12] Third, released data from a clinical trial indicated that good anti‐cancer responses can be achieved for KRAS mutant cancers based on FAK inhibition (NCT03875820).[43] We focused on a clinical‐stage FAK inhibitor: IN10018, which was previously developed by Boehringer‐Ingelheim under the name BI853520. The gene discussed is KRAS; the disease is cancer.